Long-Term Impact of Dupilumab Treatment on Systemic Cytokine Profile in Atopic Dermatitis Patients: A Cross-Sectional Study
Year: 2023
Type: preprint
Study design: Observational Study
Abstract: Atopic dermatitis (AD), a T2 inflammatory skin condition, is widely recognized as one of the most prevalent chronic and recurrent skin disorders. One of the most effective therapy for treating moderate-to-severe AD is Dupilumab, a monoclonal antibody that blocks both IL-4 and IL-13 signaling. At the same time, no comprehensive analysis of cytokines profile was made in AD patients undergoing Dupilumab therapy. The primary objective of our research was to examine the levels of main cytokines to better understanding systemic immune response in AD and to identify potential biomarkers of the effectiveness of Dupilumab treatment. AD patients demonstrated significant clinical improvements one year after initializing of Dupilumab therapy. We identified 16 cytokines that showed major difference between Dupilumab-treated patients and patients without Dupilumab therapy. Six cytokines showed correlation with AD severity and the efficacy of Dupilumab therapy. Jointly revealed cytokines could potentially predict the effectiveness of Dupilumab treatment and help to choose the precision target therapy in AD patients as well.
Source: Preprints.org
Authors: Olga Elisyutina, Maria Byazrova, Alla Litovkina, Evgeniy Smolnikov, Daria Chernushevich, Maria Sukhova, Artem Mikhailov, Dmitry Kudlay, Elena Fedenko, Nataliya Ilina, Alexander Filatov, Musa Khaitov
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funder: Russian Science Foundation
OpenAlex ID: W4387939276
